Oramed Pharmaceuticals Inc. (ORMP) | Investment Case

1. Company Snapshot

1.a. Company Description

Oramed Pharmaceuticals Inc.engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.

It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.The company was formerly known as Integrated Security Technologies, Inc.and changed its name to Oramed Pharmaceuticals Inc.

in April 2006.Oramed Pharmaceuticals Inc.was founded in 2002 and is based in New York, New York.

Show Full description

1.b. Last Insights on ORMP

Oramed Pharmaceuticals Inc.'s recent performance was driven by strong financial results, with a net income of $65.0 million for the nine months ended September 30, 2025, compared to a net loss of $6.1 million in the same period last year. The company's strategic investment portfolio yielded significant returns, including a $27 million repayment from Scilex, totaling $100 million. Additionally, the company declared a dividend distribution of common stock purchase rights, enhancing shareholder protection. Total assets increased 42% to $220.5 million, with basic earnings per share of $1.30.

1.c. Company Highlights

Last Price	2.69
Change Percentage	-1.10%
Open	2.7
Previous Close	2.72
Market Cap ( Millions)	112
Volume	55491
Year High	3.09
Year Low	1.82
M A 50	2.46
M A 200	2.28

FCF Yield	-14.35%
Dividend Yield	0.00%
ROE	-16.16%
Debt / Equity	0.59%
Net Debt / EBIDTA	363.49%
Price To Book	0.73
Price Earnings Ratio	-4.65
Price To FCF	-6.97
Price To sales	56.04
EV / EBITDA	-23.74

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Oramed Reports Fiscal Third Quarter 2025 Financial Results

Nov -17

Source: prnewswire.com

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Nov -17

Source: prnewswire.com

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Oct -23

Source: prnewswire.com

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr -28

Source: globenewswire.com

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Apr -28

Source: prnewswire.com

Oramed Pharmaceuticals Issues Letter to Shareholders

Mar -04

Source: prnewswire.com

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Feb -11

Source: prnewswire.com

3 Micro-Cap Moonshots for Fearless Investors

Jul -08

Source: investorplace.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.50%)

6. Segments

Pharmaceutical Solutions

Expected Growth: 10.5%

Oramed Pharmaceuticals Inc.'s 10.5% growth in Pharmaceutical Solutions is driven by increasing demand for oral insulin therapy, expanding partnerships with pharmaceutical companies, and growing investments in research and development. Additionally, the company's innovative technology and strong intellectual property portfolio contribute to its growth momentum.

7. Detailed Products

Oral Insulin

Oramed's flagship product, an oral insulin capsule for the treatment of diabetes, designed to replace traditional injectable insulin.

Oral GLP-1

An oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes and obesity.

Oral Exenatide

An oral formulation of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for the treatment of type 2 diabetes.

8. Oramed Pharmaceuticals Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Oramed Pharmaceuticals Inc. has a moderate threat of substitutes due to the presence of alternative treatments and medications for diabetes and other diseases.

Bargaining Power Of Customers

Oramed Pharmaceuticals Inc. has a low bargaining power of customers due to the lack of concentration of buyers in the market.

Bargaining Power Of Suppliers

Oramed Pharmaceuticals Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and equipment.

Threat Of New Entrants

Oramed Pharmaceuticals Inc. has a high threat of new entrants due to the growing demand for diabetes treatments and the presence of new biotech companies.

Intensity Of Rivalry

Oramed Pharmaceuticals Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	0.59%
Debt Cost	3.95%
Equity Weight	99.41%
Equity Cost	13.23%
WACC	13.18%
Leverage	0.59%

11. Quality Control: Oramed Pharmaceuticals Inc. passed 2 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Atara Bio

A-Score: 5.6/10

Value: 7.4

Growth: 8.0

Quality: 7.0

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

Eton Pharmaceuticals

A-Score: 4.4/10

Value: 2.2

Growth: 7.1

Quality: 4.6

Yield: 0.0

Momentum: 10.0

Volatility: 2.7

1-Year Total Return ->

Oramed Pharmaceuticals

A-Score: 4.1/10

Value: 7.8

Growth: 4.8

Quality: 3.0

Yield: 0.0

Momentum: 6.0

Volatility: 3.0

1-Year Total Return ->

Aadi Bioscience

A-Score: 3.9/10

Value: 8.0

Growth: 5.4

Quality: 4.5

Yield: 0.0

Momentum: 3.5

Volatility: 2.0

1-Year Total Return ->

Century Therapeutics

A-Score: 3.8/10

Value: 9.6

Growth: 5.4

Quality: 5.2

Yield: 0.0

Momentum: 0.5

Volatility: 2.0

1-Year Total Return ->

Sutro Biopharma

A-Score: 3.0/10

Value: 9.4

Growth: 2.3

Quality: 4.9

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

30.37%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

13.18%

Oramed Pharmaceuticals Inc. - US68403P2039

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ORMP

1.c. Company Highlights

Average Growth

Stable Momentum

Fairly Valued

Earnings Beats

Lower Growth

Medium Volatility

Average Yield

Average Quality

Earnings Miss

Cheaper

Lower Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.50%)

6. Segments

Pharmaceutical Solutions

Expected Growth: 10.5%

7. Detailed Products

Oral Insulin

Oral GLP-1

Oral Exenatide

8. Oramed Pharmaceuticals Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Oramed Pharmaceuticals Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.69$

Current Price

2.69$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA